1.阿霉素
2.亚德里亚霉素
1.an antibiotic obtained from a bacterium.
1.Half the women received a combination therapy of trabectedin and a chemotherapy drug called pegylated liposomal doxorubicin.
一半的女性接受trabectedin和称为脂质体阿霉素聚乙二醇的化疗药物组成的混合疗法。
2.Chemotherapy-treated patients usually get a combination of three drugs -- fluorouracil, doxorubicin, and cyclophosphamide.
化疗治疗的患者，通常应用的三种药物是-氟脲嘧啶，阿霉素和环磷酰胺。
3.This translates into enhanced therapeutic efficacy for drugs like doxorubicin that have intracellular site of action.
继而又转化成提高阿霉素这类作用于细胞内位点药物的治疗效果。
4.OBJECTIVE To compare the antitumor activity between stealth liposomal doxorubicin and regular liposomal doxorubicin.
目的比较阿霉素隐形脂质体与普通脂质体的抗肿瘤活性。
5.Objective To compare the antitumor efficacy between liposomal doxorubicin hydrochloride and CAELYX injection.
目的比较盐酸多柔比星脂质体注射液与市售楷莱注射液的体内抗肿瘤作用。
6.The targeted delivery of liposomal anticancer drug doxorubicin results in better therapeutic efficacy towards cells in vitro.
向细胞靶向递送脂质体抗癌药物阿霉素可以在体外获得更好的疗效。
7.The combination of sorafenib and doxorubicin in patients with advanced HCC has not been evaluated in a phase 2 or 3 trial.
目前还没有2期或3期试验对索拉非尼与多柔比星联用治疗晚期HCC患者进行评价。
8.Expressions of apoptosis-related genes were up-regulated in tissues of doxorubicin-induced cardiomyopathy.
氧化和能量代谢相关基因的表达在多柔比星心肌病时下调。
9.CONCLUSION The antitumor activity of stealth liposomal doxorubicin in vivo is higher than that of the regular.
结论同普通脂质体给药组相比，阿霉素隐形脂质体给药组的抗肿瘤活性显著地提高。
10.Results AOT-alginate nanoparticles demonstrated sustained release of doxorubicin over a 15-day period in vitro.
结果：体外15天以上的试验显示AOT-藻酸盐纳米粒对阿霉素有缓释作用。